All material subject to strictly enforced copyright laws. © 2022 Euromoney Institutional Investor PLC group
Syndicated Loans

GSK ratings under pressure with Tesaro buy, states Moody's

Scrutiny

Moody’s has slapped a negative outlook on the UK’s GlaxoSmithKline, after the pharmaceuticals company said it planned a debt funded $5.1bn deal for US oncology company Tesaro.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login
We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree